These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 21655476

  • 1. [Examination of ERCC1 expression in lung cancer patients treated with platinum-based chemotherapy].
    Moldvay J, Pápay J, Puskás R, Furák J, Losonczy G, Matolcsy A.
    Magy Onkol; 2011 Jun; 55(2):105-9. PubMed ID: 21655476
    [Abstract] [Full Text] [Related]

  • 2. Decreased ERCC1 Expression After Platinum-Based Neoadjuvant Chemotherapy in non-Small Cell Lung Cancer.
    Podmaniczky E, Fábián K, Pápay J, Puskás R, Gyulai M, Furák J, Tiszlavicz L, Losonczy G, Tímár J, Moldvay J.
    Pathol Oncol Res; 2015 Apr; 21(2):423-31. PubMed ID: 25194563
    [Abstract] [Full Text] [Related]

  • 3. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.
    Ronchi CL, Sbiera S, Kraus L, Wortmann S, Johanssen S, Adam P, Willenberg HS, Hahner S, Allolio B, Fassnacht M.
    Endocr Relat Cancer; 2009 Sep; 16(3):907-18. PubMed ID: 19240185
    [Abstract] [Full Text] [Related]

  • 4. Platinum-based chemotherapy in lung cancer affects the expression of certain biomarkers including ERCC1.
    Pápay J, Sápi Z, Egri G, Gyulai M, Szende B, Losonczy G, Tímár J, Moldvay J.
    Pathol Oncol Res; 2009 Sep; 15(3):445-50. PubMed ID: 19253035
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [ERCC1 expression and outcomes of neo-adjuvant chemotherapy in elderly patients with non-small cell lung cancer].
    Li GF, Deng SJ, Weng WW, Guo G, Chen N.
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Sep; 30(9):2131-3. PubMed ID: 20855270
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.
    Sodja E, Knez L, Kern I, Ovčariček T, Sadikov A, Cufer T.
    Eur J Cancer; 2012 Dec; 48(18):3378-85. PubMed ID: 22795264
    [Abstract] [Full Text] [Related]

  • 12. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.
    Okuda K, Sasaki H, Dumontet C, Kawano O, Yukiue H, Yokoyama T, Yano M, Fujii Y.
    Lung Cancer; 2008 Oct; 62(1):105-12. PubMed ID: 18395930
    [Abstract] [Full Text] [Related]

  • 13. Comparison of two ERCC1 antibodies as prognostic and predictive biomarkers for early non-small cell lung cancer.
    Muley TR, Sianidou M, Thomas M, Bischoff H, Dienemann H, Meister M, Schneider MA, Schnabel PA, Warth A.
    Anticancer Res; 2014 Jul; 34(7):3707-13. PubMed ID: 24982391
    [Abstract] [Full Text] [Related]

  • 14. The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis.
    Chen S, Zhang J, Wang R, Luo X, Chen H.
    Lung Cancer; 2010 Oct; 70(1):63-70. PubMed ID: 20541281
    [Abstract] [Full Text] [Related]

  • 15. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
    Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria JC, Fouret P.
    Clin Cancer Res; 2007 Jul 01; 13(13):3855-9. PubMed ID: 17606717
    [Abstract] [Full Text] [Related]

  • 16. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A, Sørensen JB.
    Lung Cancer; 2009 May 01; 64(2):131-9. PubMed ID: 18804893
    [Abstract] [Full Text] [Related]

  • 17. Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer.
    Ikeda S, Takabe K, Suzuki K.
    Pathol Int; 2009 Dec 01; 59(12):863-7. PubMed ID: 20021611
    [Abstract] [Full Text] [Related]

  • 18. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F, Sun X, Sun N, Qin S, Cheng H, Feng J, Chen B, Cheng L, Lu Z, Ji J, Zhou Y.
    Am J Clin Oncol; 2010 Oct 01; 33(5):489-94. PubMed ID: 20351547
    [Abstract] [Full Text] [Related]

  • 19. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
    Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Viñolas N, Paz-Ares L, Lopez-Vivanco G, Muñoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D, Rosell R.
    J Clin Oncol; 2007 Jul 01; 25(19):2747-54. PubMed ID: 17602080
    [Abstract] [Full Text] [Related]

  • 20. ERCC1 and topoisomerase I expression in small cell lung cancer: prognostic and predictive implications.
    Sereno M, Cejas P, Moreno V, Belda-Iniesta C, López R, Nistal M, Feliu J, De Castro Carpeño J.
    Int J Oncol; 2012 Jun 01; 40(6):2104-10. PubMed ID: 22344449
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.